Inappropriate prescription of loop diuretics for calcium channel blocker-related peripheral edema: Lessons from

Jesús Daniel Meléndez-Flores1, Mónica Sánchez-Cárdenas1

  • 1Internal Medicine Department, "Dr. José Eleuterio González" University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Insights

Calcium Channel Blockers (CCB) can cause peripheral edema, often mistaken for fluid overload. This article explains CCB-induced edema mechanisms and offers strategies to help physicians manage this common side effect.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Calcium Channel Blockers (CCB) are widely prescribed for hypertension.
  • Peripheral edema affects up to 70% of patients on CCBs.
  • Physicians often misinterpret CCB-induced edema as fluid overload.

Purpose of the Study:

  • To elucidate the mechanisms behind CCB-induced vasodilatory edema.
  • To differentiate CCB edema from fluid overload.
  • To propose management strategies for CCB-induced peripheral edema.

Main Methods:

  • Review of existing literature on CCB pharmacology and side effects.
  • Analysis of physiological mechanisms causing peripheral edema with CCB use.
  • Clinical case review and guideline analysis.

Main Results:

  • CCB-induced edema results from arteriolar vasodilation, not systemic fluid overload.
  • Diuretic therapy is often ineffective and can cause adverse effects like electrolyte imbalance and acute kidney injury.
  • Understanding the vasodilatory mechanism is key to appropriate management.

Conclusions:

  • CCB-induced peripheral edema is primarily a pharmacokinetic effect, not a sign of fluid overload.
  • Mismanagement with diuretics can lead to serious complications.
  • Physicians should consider alternative strategies for managing CCB-induced edema.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
277
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
398
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
393
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
674
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
385